Related references
Note: Only part of the references are listed.Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
Nancy M. Archin et al.
AIDS (2008)
Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system
Scott Letendre et al.
ARCHIVES OF NEUROLOGY (2008)
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4+ T cells
Shailesh K. Choudhary et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Sarah Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice
Paul W. Denton et al.
PLOS MEDICINE (2008)
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency
Mudit Tyagi et al.
EMBO JOURNAL (2007)
c-Myc and sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter
Guochun Jiang et al.
JOURNAL OF VIROLOGY (2007)
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes
Jialing Huang et al.
NATURE MEDICINE (2007)
HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR
Zachary Klase et al.
BMC MOLECULAR BIOLOGY (2007)
Regulation of HIV-1 latency by T-cell activation
Samuel A. Williams et al.
CYTOKINE (2007)
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
Frank Maldarelli et al.
PLOS PATHOGENS (2007)
Experimental approaches to the study of HIV-1 latency
Yefei Han et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1
Michael W. Melkus et al.
NATURE MEDICINE (2006)
Liver-related deaths in persons infected with the human immunodeficiency virus -: The D:A:D study
Rainer Weber
ARCHIVES OF INTERNAL MEDICINE (2006)
Controlling the elongation phase of transcription with P-TEFb
B. Matija Peterlin et al.
MOLECULAR CELL (2006)
The survival benefits of AIDS treatment in the United States
Rochelle P. Walensky et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Residual human immunodeficiency virus type 1 viremia in some patients on Antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells
JR Bailey et al.
JOURNAL OF VIROLOGY (2006)
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells
Kara G. Lassen et al.
PLOS PATHOGENS (2006)
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces tat-independent HIV-1 expression but blunts cell activation
V Klichko et al.
JOURNAL OF VIROLOGY (2006)
NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation
SA Williams et al.
EMBO JOURNAL (2006)
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
MC Strain et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART
FX Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Prostratin antagonizes HIV latency by activating NF-κB
SA Williams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV:: Intrinsic stability predicts lifelong persistence
MC Strain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy
AD Shen et al.
JOURNAL OF VIROLOGY (2003)
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy
J Kulkosky et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART
J Kulkosky et al.
BLOOD (2001)
Prevalence and predictive value of intermittent viremia with combination HIV therapy
DV Havlir et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
M Fischer et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1
JJ Coull et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
